

Sharmila Banerjee

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5312310/publications.pdf>

Version: 2024-02-01

155
papers

2,727
citations

218677

26
h-index

254184

43
g-index

155
all docs

155
docs citations

155
times ranked

2305
citing authors

#	ARTICLE	IF	CITATIONS
1	Evolution of Tc-99m in diagnostic radiopharmaceuticals. <i>Seminars in Nuclear Medicine</i> , 2001, 31, 260-277.	4.6	212
2	Lutetium-177 Therapeutic Radiopharmaceuticals: Linking Chemistry, Radiochemistry, and Practical Applications. <i>Chemical Reviews</i> , 2015, 115, 2934-2974.	47.7	203
3	<i>N</i> -Vanillylidene- <i>l</i> -histidine: Experimental Charge Density Analysis of a Double Zwitterionic Amino Acid Schiff-Base Compound. <i>Crystal Growth and Design</i> , 2010, 10, 1665-1676.	3.0	81
4	Comparative studies of ¹⁷⁷ Lu-EDTMP and ¹⁷⁷ Lu-DOTMP as potential agents for palliative radiotherapy of bone metastasis. <i>Applied Radiation and Isotopes</i> , 2008, 66, 1196-1205.	1.5	68
5	¹⁷⁷ Lu-EDTMP: A Viable Bone Pain Palliative in Skeletal Metastasis. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2008, 23, 202-213.	1.0	64
6	¹⁷⁷ Lu-labeled cyclic polyaminophosphonates as potential agents for bone pain palliation. <i>Applied Radiation and Isotopes</i> , 2002, 57, 177-184.	1.5	61
7	Preparation and preliminary studies on ¹⁷⁷ Lu-labeled hydroxyapatite particles for possible use in the therapy of liver cancer. <i>Nuclear Medicine and Biology</i> , 2008, 35, 589-597.	0.6	58
8	A novel [99mTcN] ₂ ⁺ complex of metronidazole xanthate as a potential agent for targeting hypoxia. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2005, 15, 3398-3401.	2.2	55
9	¹⁷⁰ Tm-EDTMP: a potential cost-effective alternative to ⁸⁹ SrCl ₂ for bone pain palliation. <i>Nuclear Medicine and Biology</i> , 2009, 36, 561-568.	0.6	55
10	Theranostic Applications of Lutetium-177 in Radionuclide Therapy. <i>Current Radiopharmaceuticals</i> , 2015, 9, 94-101.	0.8	52
11	Clinical utility of ¹⁷⁷ Lu-DOTATATE PRRT in somatostatin receptor-positive metastatic medullary carcinoma of thyroid patients with assessment of efficacy, survival analysis, prognostic variables, and toxicity. <i>Head and Neck</i> , 2020, 42, 401-416.	2.0	50
12	Preparation and preliminary biological evaluation of ¹⁷⁷ Lu-labelled hydroxyapatite as a promising agent for radiation synovectomy of small joints. <i>Nuclear Medicine Communications</i> , 2006, 27, 661-668.	1.1	45
13	Therapeutic efficacy, prognostic variables and clinical outcome of ¹⁷⁷ Lu-PSMA-617 PRLT in progressive mCRPC following multiple lines of treatment: prognostic implications of high FDG uptake on dual tracer PET-CT vis-à-vis Gleason score in such cohort. <i>British Journal of Radiology</i> , 2019, 92, 20190380.	2.2	44
14	Differential Uptake of ⁶⁸ Ga-PSMA-HBED-CC (PSMA-11) in Low-Grade Versus High-Grade Gliomas in Treatment-Naive Patients. <i>Clinical Nuclear Medicine</i> , 2019, 44, e318-e322.	1.3	40
15	¹⁷⁷ Lu-EDTMP for Treatment of Bone Pain in Patients with Disseminated Skeletal Metastases. <i>Journal of Nuclear Medicine Technology</i> , 2014, 42, 55-61.	0.8	39
16	Evaluation of ^{99m} Tc(CO) ₃ complex of 2-methyl-5-nitroimidazole as an agent for targeting tumor hypoxia. <i>Bioorganic and Medicinal Chemistry</i> , 2006, 14, 7666-7670.	3.0	38
17	Development of a Radioimmunoassay Procedure for Aflatoxin B ₁ Measurement. <i>Journal of Agricultural and Food Chemistry</i> , 2003, 51, 843-846.	5.2	37
18	¹⁷⁵ Yb labeled polyaminophosphonates as potential agents for bone pain palliation. <i>Applied Radiation and Isotopes</i> , 2004, 60, 635-642.	1.5	37

#	ARTICLE	IF	CITATIONS
19	On the isolation and evaluation of a novel unsubstituted 5-nitroimidazole derivative as an agent to target tumor hypoxia. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 5233-5237.	2.2	36
20	On the preparation of a therapeutic dose of ¹⁷⁷ Lu-labeled DOTA- ⁶⁷ Ge using indigenously produced ¹⁷⁷ Lu in medium flux reactor. <i>Applied Radiation and Isotopes</i> , 2007, 65, 301-308.	1.5	35
21	Surface modified silk fibroin nanoparticles for improved delivery of doxorubicin: Development, characterization, in-vitro studies. <i>International Journal of Biological Macromolecules</i> , 2020, 164, 2018-2027.	7.5	34
22	A novel ¹⁷⁷ Lu-labeled porphyrin for possible use in targeted tumor therapy. <i>Nuclear Medicine and Biology</i> , 2010, 37, 655-663.	0.6	32
23	Synthesis and evaluation of 2-, 4-, 5-substituted nitroimidazole-iminodiacetic acid- ^{99m} Tc(CO) ₃ complexes to target hypoxic tumors. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2010, 53, 535-542.	1.0	30
24	Emergence and present status of Lu-177 in targeted radiotherapy: the Indian scenario. <i>Radiochimica Acta</i> , 2012, 100, 115-126.	1.2	30
25	^{99m} Tc-labeling of colchicine using [^{99m} Tc(CO) ₃ (H ₂ O) ₃] ⁺ and [^{99m} TcN] ₂ ⁺ core for the preparation of potential tumor-targeting agents. <i>Bioorganic and Medicinal Chemistry</i> , 2006, 14, 793-799.	3.0	28
26	Preparation and preliminary biological evaluation of a ¹⁷⁷ Lu labeled sanazole derivative for possible use in targeting tumor hypoxia. <i>Bioorganic and Medicinal Chemistry</i> , 2004, 12, 6077-6084.	3.0	27
27	¹⁷⁷ Lu-DOTA-lanreotide: a novel tracer as a targeted agent for tumor therapy. <i>Nuclear Medicine and Biology</i> , 2004, 31, 753-759.	0.6	27
28	¹⁷⁷ Lu-DOTMP: A viable agent for palliative radiotherapy of painful bone metastasis. <i>Radiochimica Acta</i> , 2008, 96, 55-61.	1.2	27
29	[^{186/188} Re] rhenium-ethylene dicysteine (Re-Ec): preparation and evaluation for possible use in endovascular brachytherapy. <i>Nuclear Medicine and Biology</i> , 2000, 27, 189-197.	0.6	26
30	Tc- ^{99m} and Re-186 complexes of tetraphosphonate ligands and their biodistribution pattern in animal models. <i>Nuclear Medicine and Biology</i> , 2001, 28, 205-213.	0.6	26
31	On the structural modification of 2-nitroimidazole- ^{99m} Tc(CO) ₃ complex, a hypoxia marker, for improving in vivo pharmacokinetics. <i>Nuclear Medicine and Biology</i> , 2012, 39, 1236-1242.	0.6	26
32	A study on nitroimidazole- ^{99m} Tc(CO) ₃ complexes as hypoxia marker: Some observations towards possible improvement in in vivo efficacy. <i>Nuclear Medicine and Biology</i> , 2014, 41, 600-610.	0.6	26
33	Clinical translation of ¹⁷⁷ Lu-labeled PSMA-617: Initial experience in prostate cancer patients. <i>Nuclear Medicine and Biology</i> , 2016, 43, 296-302.	0.6	26
34	Preparation and bioevaluation of a ^{99m} Tc-labeled chlorambucil analog as a tumor targeting agent. <i>Applied Radiation and Isotopes</i> , 2009, 67, 1644-1649.	1.5	25
35	Biologic Evaluation of a Novel ¹⁸⁸ Re-Labeled Porphyrin in Mice Tumor Model. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2010, 25, 47-54.	1.0	25
36	^{99m} Tc-labeling studies of a modified metronidazole and its biodistribution in tumor bearing animal models. <i>Nuclear Medicine and Biology</i> , 2003, 30, 127-134.	0.6	24

#	ARTICLE	IF	CITATIONS
37	Convenient Preparation of [⁶⁸ Ga]DKFZ-PSMA-11 Using a Robust Single-Vial Kit and Demonstration of Its Clinical Efficacy. <i>Molecular Imaging and Biology</i> , 2016, 18, 420-427.	2.6	23
38	Radiopharmaceuticals for metastatic bone pain palliation: available options in the clinical domain and their comparisons. <i>Clinical and Experimental Metastasis</i> , 2017, 34, 1-10.	3.3	23
39	⁶⁸ Ga-labeled Ciprofloxacin Conjugates as Radiotracers for Targeting Bacterial Infection. <i>Chemical Biology and Drug Design</i> , 2016, 87, 680-686.	3.2	22
40	A zwitterionic pH responsive ESIPT-Based fluorescence Turn-On Al ³⁺ ion sensing probe and its bioimaging applications. <i>Sensors and Actuators B: Chemical</i> , 2017, 253, 1012-1025.	7.8	22
41	Preparation and biological evaluation of ¹⁵³ Sm-DOTMP as a potential agent for bone pain palliation. <i>Nuclear Medicine Communications</i> , 2004, 25, 1169-1176.	1.1	20
42	Preparation of Patient Doses of ¹⁷⁷ Lu-DOTA-TATE Using Indigenously Produced ¹⁷⁷ Lu: The Indian Experience. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2011, 26, 395-400.	1.0	19
43	Radiosynovectomy of Painful Synovitis of Knee Joints Due to Rheumatoid Arthritis by Intra-Articular Administration of ¹⁷⁷ Lu-Labeled Hydroxyapatite Particulates: First Human Study and Initial Indian Experience. <i>World Journal of Nuclear Medicine</i> , 2015, 14, 81-88.	0.5	19
44	Radiochemical studies of ^{99m} Tc complexes of modified cysteine ligands and bifunctional chelating agents. <i>Nuclear Medicine and Biology</i> , 1999, 26, 555-561.	0.6	18
45	Potential ¹⁶⁶ Ho radiopharmaceuticals for intravascular radiation therapy (IVRT)-I: [¹⁶⁶ Ho] holmium labeled ethylene dicycysteine. <i>Nuclear Medicine and Biology</i> , 2001, 28, 309-317.	0.6	18
46	¹⁶⁶ Ho-Labeled Hydroxyapatite Particles: A Possible Agent for Liver Cancer Therapy. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2009, 24, 7-14.	1.0	17
47	Preparation of ¹⁷⁷ Lu-Labeled Oxine in Lipiodol as a Possible Agent for Therapy of Hepatocellular Carcinoma: A Preliminary Animal Study. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2010, 25, 539-543.	1.0	17
48	Pharmacokinetic, Dosimetry and Toxicity Study of ¹⁷⁷ Lu-EDTMP in Patients: Phase 0/I study. <i>Current Radiopharmaceuticals</i> , 2015, 9, 71-84.	0.8	17
49	Syntheses of potential spin probes for biomembranes - tempo and proxyl nitroxides of lithocholic acid. <i>Tetrahedron</i> , 1992, 48, 9939-9950.	1.9	16
50	An efficient and stereoselective synthesis of (2R,2 ² S)-1-O-(2 ² -hydroxyhexadecyl)glycerol and its oxo analogs: Potential antitumour compounds from Shark Liver Oil. <i>Tetrahedron</i> , 1996, 52, 6437-6452.	1.9	16
51	Synthesis and bio-evaluation of a new fatty acid derivative for myocardial imaging. <i>Bioorganic and Medicinal Chemistry</i> , 2008, 16, 7927-7931.	3.0	16
52	Preparation of ¹⁶⁶ Ho-oxine-lipiodol and its preliminary bioevaluation for the potential application in therapy of liver cancer. <i>Nuclear Medicine Communications</i> , 2009, 30, 362-367.	1.1	16
53	Synthesis and Biological Evaluation of ⁹⁰ Y-Labeled Porphyrin-DOTA Conjugate: A Potential Molecule for Targeted Tumor Therapy. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2013, 28, 651-656.	1.0	16
54	Formulation, Preclinical Evaluation, and Preliminary Clinical Investigation of an In-House Freeze-Dried EDTMP Kit Suitable for the Preparation of ¹⁷⁷ Lu-EDTMP. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2014, 29, 412-421.	1.0	16

#	ARTICLE	IF	CITATIONS
55	â€”4+1â€” Mixed Ligand Strategy for the Preparation of 99m Tc-Radiopharmaceuticals for Hypoxia Detecting Applications. <i>ChemistrySelect</i> , 2017, 2, 2910-2916.	1.5	16
56	An estradiol-conjugate for radiolabelling with 177Lu: an attempt to prepare a radiotherapeutic agent. <i>Bioorganic and Medicinal Chemistry</i> , 2005, 13, 4315-4322.	3.0	15
57	Synthesis and evaluation of ether containing 99mTcâ€”nitrido dithiocarbamate complexes as brain perfusion imaging agent. <i>Applied Radiation and Isotopes</i> , 2006, 64, 361-367.	1.5	15
58	Preparation and bioevaluation of 99mTc-carbonyl complex of 5-hydroxy tryptamine derivative. <i>Applied Radiation and Isotopes</i> , 2006, 64, 888-892.	1.5	15
59	Radiolabeling, Stability Studies, and Pharmacokinetic Evaluation of Thulium-170-Labeled Acyclic and Cyclic Polyaminopolyphosphonic Acids. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2013, 28, 737-745.	1.0	15
60	Synthesis of 2'-(3-â€”benzyloxy-24-norcholesterol-23-yl)-2',4',4'-trimethyl-4',5'-dihydrooxazoline-n-oxyl - a new potential spin probe for biomembranes. <i>Tetrahedron</i> , 1992, 48, 133-148.	1.9	14
61	Preparation of DOTA-TATE and DOTA-NOC freeze-dried kits for formulation of patient doses of 177Lu-labeled agents and their comparison for peptide receptor radionuclide therapy application. <i>Journal of Radioanalytical and Nuclear Chemistry</i> , 2014, 299, 1389-1398.	1.5	14
62	Theranostic Treatment of Metastatic Bone Pain With 177Lu-DOTMP. <i>Clinical Nuclear Medicine</i> , 2016, 41, 966-967.	1.3	14
63	Modulation of in vivo distribution through chelator: Synthesis and evaluation of a 2-nitroimidazoleâ€”dipicolylamineâ€”99mTc(CO)3 complex for detecting tumor hypoxia. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 46-50.	2.2	14
64	99mTcN complexes of tert-butyl dithiocarbamate and methoxyisobutyl dithiocarbamate as myocardial and brain imaging agents. <i>Nuclear Medicine Communications</i> , 2005, 26, 1013-1019.	1.1	13
65	Preparation and preliminary biological evaluation of a 177Lu labeled nitroimidazole derivative for possible use in targeted tumor therapy. <i>Radiochimica Acta</i> , 2006, 94, 375-380.	1.2	13
66	Preparation and preliminary bioevaluation of 99mTc(CO)3-11â€”progesterone derivative prepared via click chemistry route. <i>Nuclear Medicine and Biology</i> , 2010, 37, 997-1004.	0.6	13
67	A Freeze-Dried Kit for the Preparation of 188Re-HEDP for Bone Pain Palliation: Preparation and Preliminary Clinical Evaluation. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2016, 31, 139-144.	1.0	12
68	Production, separation and supply prospects of ⁶⁷ Cu with the development of fast neutron sources and photonuclear technology. <i>Radiochimica Acta</i> , 2018, 106, 549-557.	1.2	12
69	Formulation and evaluation of letrozole-loaded spray dried liposomes with PEs for topical application. <i>Journal of Liposome Research</i> , 2020, 30, 274-284.	3.3	12
70	Availability of both [177Lu]Lu-DOTA-TATE and [90Y]Y-DOTATATE as PRRT agents for neuroendocrine tumors: can we evolve a rational sequential duo-PRRT protocol for large volume resistant tumors?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 756-758.	6.4	12
71	Examining Absorbed Doses of Indigenously Developed ¹⁷⁷ Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer Patients at Baseline and During Course of Peptide Receptor Radioligand Therapy. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2021, 36, 292-304.	1.0	12
72	Studies on the preparation and stability of samarium-153 propylene diamine tetramethylene phosphonate (PDTMP) complex as a bone seeker. <i>Applied Radiation and Isotopes</i> , 2000, 53, 987-991.	1.5	11

#	ARTICLE	IF	CITATIONS
73	186Re-1,4,8,11-tetraaza cyclotetradecyl-1,4,8,11-tetramethylene phosphonic acid: a novel agent for possible use in metastatic bone-pain palliation. <i>Nuclear Medicine and Biology</i> , 2001, 28, 709-717.	0.6	11
74	Preparation and <i>In-Vivo</i> Evaluation of ¹⁸⁸ Re(CO) ₃ -Colchicine Complex for Use as Tumor-Targeting Agent. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2008, 23, 741-748.	1.0	11
75	Synthesis and Preliminary Bioevaluation of ^{99m} Tc(CO) ₃ -17 β -Triazolylandrosterone-4-ene-3-one Derivative Prepared via Click Chemistry Route. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2011, 26, 539-545.	1.0	11
76	Proxyl nitroxide of lithocholic acid: A potential spin probe for model membranes. <i>Bioorganic and Medicinal Chemistry</i> , 1993, 1, 341-347.	3.0	10
77	A novel ^{99m} Tc-labeled testosterone derivative as a potential agent for targeting androgen receptors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2006, 16, 5788-5792.	2.2	10
78	A ^{99m} Tc-Labeled Misonidazole Analogue: Step Toward a ^{99m} Tc-Alternative to [¹⁸ F]Fluoromisonidazole for Detecting Tumor Hypoxia. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2015, 30, 79-86.	1.0	10
79	Preparation of clinical-scale ¹⁷⁷ Lu-Rituximab: Optimization of protocols for conjugation, radiolabeling, and freeze-dried kit formulation. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2017, 60, 234-241.	1.0	10
80	¹⁰⁹ Pd labeled 5,10,15,20-tetrakis[4-carboxymethyleneoxyphenyl]porphyrin: a Potential Agent for Targeted Tumor Therapy. <i>Current Radiopharmaceuticals</i> , 2012, 5, 340-347.	0.8	10
81	Reverse discordance™ between ⁶⁸ Ga-DOTA-NOC PET/CT and ¹⁷⁷ Lu-DOTA-TATE posttherapy scan. <i>Nuclear Medicine Communications</i> , 2011, 32, 654-658.	1.1	9
82	Radiosynthesis and Biological Evaluation of ⁶⁸ Ga-Labeled Colchicine Conjugates. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2014, 29, 251-256.	1.0	9
83	¹⁷⁷ Lu-labeled carbon nanospheres: a new entry in the field of targeted radionanomedicine. <i>RSC Advances</i> , 2016, 6, 50761-50769.	3.6	9
84	Juglone-ascorbic acid synergy inhibits metastasis and induces apoptotic cell death in poorly differentiated thyroid carcinoma by perturbing SOD and catalase activities. <i>Journal of Biochemical and Molecular Toxicology</i> , 2018, 32, e22176.	3.0	9
85	Studies on Efficacy of a Novel ¹⁷⁷ Lu-Labeled Porphyrin Derivative in Regression of Tumors in Mouse Model. <i>Current Radiopharmaceuticals</i> , 2011, 4, 150-160.	0.8	9
86	A novel concept of radiosynthesis of a ^{99m} Tc-labeled dimeric RGD peptide as a potential radiotracer for tumor imaging. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 1808-1812.	2.2	8
87	Neutral ^{99m} Tc(CO) ₃ complexes of κ^2 -nitroimidazoles for the detection of tumor hypoxia. <i>Journal of Radioanalytical and Nuclear Chemistry</i> , 2016, 307, 69-77.	1.5	8
88	¹⁷⁷ Lu-DOTMP induces G2/M cell cycle arrest and apoptosis in MG63 cell line. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2018, 61, 837-846.	1.0	8
89	Clinical utility of ¹⁸⁸ Rhenium-hydroxyethylidene-1,1-diphosphonate as a bone pain palliative in multiple malignancies. <i>World Journal of Nuclear Medicine</i> , 2018, 17, 228-235.	0.5	8
90	Serum prolactin in seizure disorders. <i>Indian Pediatrics</i> , 2004, 41, 827-31.	0.4	8

#	ARTICLE	IF	CITATIONS
91	On the synthesis, isolation, and radiochemical studies for the preparation of in-house kits for ^{99m} Tc-meso- and d,l-HMPAO: a few additional observations. <i>Nuclear Medicine and Biology</i> , 1999, 26, 327-338.	0.6	7
92	Syntheses and radiolabeling of cysteine-oximes and pharmacological behaviour of their ^{99m} Tc complexes. <i>Applied Radiation and Isotopes</i> , 2000, 52, 69-76.	1.5	7
93	Preparation of ^{99m} Tc(CO) ₃ -Carboxymethylthioethyl Iminodiacetic Acid and Evaluation as a Potential Renal Imaging Agent. <i>Current Radiopharmaceuticals</i> , 2012, 5, 65-70.	0.8	7
94	Preparation and evaluation of a ^{99m} TcNâ€“PNP complex of sanazole analogue for detecting tumor hypoxia. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 1394-1397.	2.2	7
95	Synthesis and evaluation of a phenylbenzothiazole-based ^{99m} Tc(CO) ₃ -radiotracer for possible application in imaging of ¹² I-amyloid plaques in Alzheimerâ€™s disease. <i>Journal of Radioanalytical and Nuclear Chemistry</i> , 2014, 302, 1339-1344.	1.5	7
96	Preparation and bioevaluation of [^{99m} TcN]2+-labeled tetrameric complex of E-c(RGDfK) ₂ as a radiotracer for imaging α v β 3 integrins in tumors. <i>Journal of Radioanalytical and Nuclear Chemistry</i> , 2016, 309, 923.	1.5	7
97	Synthesis and evaluation of a novel ^{99m} TcN(PNP)-complex with metronidazole isocyanide ligand as a marker for tumor hypoxia. <i>Journal of Radioanalytical and Nuclear Chemistry</i> , 2016, 308, 363-369.	1.5	7
98	Stereoselective total synthesis of (2R,2â€“S,3Z)-1-O-(2-methoxyhexadecenyl) glycerol and (2R,2â€“S)-1-(2â€“methoxyhexadecyl)glycerol-potential antitumour compounds from Shark liver oil. <i>Tetrahedron</i> , 1995, 51, 4723-4732.	1.9	6
99	Evaluation of new positively charged 11â€“and 12â€“carbon ^{99m} Tc-labeled fatty acid derivatives for myocardial imaging. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2010, 53, 580-585.	1.0	6
100	Synthesis, radiolabeling and evaluation of a new positively charged ^{99m} Tc-labeled fatty acid derivative for myocardial imaging. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2011, 54, 150-156.	1.0	6
101	Stereoselective synthesis of an iodinated resveratrol analog: Preliminary bioevaluation studies of the radioiodinated species. <i>Applied Radiation and Isotopes</i> , 2011, 69, 996-1001.	1.5	6
102	Preparation of Therapeutic Dose of ¹⁷⁷ Lu-DOTA-TATE Using a Novel Single Vial Freeze-dried Kit: A Comparison with â€“In-situâ€“ Preparation at Hospital Radiopharmacy. <i>Current Radiopharmaceuticals</i> , 2014, 7, 12-19.	0.8	6
103	Evaluation of ¹⁷⁷ Lu-EDTMP in Dogs with Spontaneous Tumor Involving Bone: Pharmacokinetics, Dosimetry and Therapeutic Efficacy. <i>Current Radiopharmaceuticals</i> , 2015, 9, 64-70.	0.8	6
104	Synthesis and comparative <i>in vivo</i> evaluation of ^{99m} Tc(³ CO) ₃ -labeled PEGylated and non-PEGylated cRGDFK peptide monomers. <i>Chemical Biology and Drug Design</i> , 2017, 89, 371-378.	3.2	6
105	Preparation and preliminary evaluation of a tris-metronidazole- ^{99m} Tc(CO) ₃ complex for targeting tumor hypoxia. <i>Journal of Radioanalytical and Nuclear Chemistry</i> , 2018, 317, 1203-1210.	1.5	6
106	Potential immunomodulatory effect of allelochemical juglone in mice vaccinated with BCG. <i>Toxicon</i> , 2019, 157, 43-52.	1.6	6
107	Preparation and <i>in vivo</i> evaluation of ^{99m} TcN-tertiary butyl xanthate as a potential myocardial agent. <i>Applied Radiation and Isotopes</i> , 2006, 64, 663-667.	1.5	5
108	Radiosynthesis and <i>in vitro</i> evaluation of ^{99m} Tc(CO) ₃ -labeled folic acid derivative. <i>Journal of Radioanalytical and Nuclear Chemistry</i> , 2011, 290, 89-93.	1.5	5

#	ARTICLE	IF	CITATIONS
109	Effect of lipophilicity on biological properties of ¹⁰⁹ Pd-porphyrin complexes: a preliminary investigation. <i>Journal of Porphyrins and Phthalocyanines</i> , 2012, 16, 64-71.	0.8	5
110	Improved Kit Formulation for Preparation of ^{99m} Tc-HYNIC-TOC: Results of Preliminary Clinical Evaluation in Imaging Patients with Neuroendocrine Tumors. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2014, 29, 387-394.	1.0	5
111	Utility of ^{99m} Tc-Hynic-TOC in ¹³¹ I Whole-Body Scan Negative Thyroid Cancer Patients with Elevated Serum Thyroglobulin Levels. <i>World Journal of Nuclear Medicine</i> , 2015, 14, 101.	0.5	5
112	Syntheses and biological evaluation of ^{99m} Tc-HYNIC-fatty acid complexes for myocardial imaging. <i>RSC Advances</i> , 2015, 5, 93374-93385.	3.6	5
113	Formulation and evaluation of freeze-dried DOTMP kit for the preparation of clinical-scale ¹⁷⁷ Lu-DOTMP and ¹⁵³ Sm-DOTMP at the hospital radiopharmacy. <i>Radiochimica Acta</i> , 2015, 103, 595-604.	1.2	5
114	In Vitro Evaluation of ¹⁸⁸ Re-HEDP: A Mechanistic View of Bone Pain Palliations. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2017, 32, 184-191.	1.0	5
115	Preparation and preliminary bioevaluation of ⁶⁸ Ga-oxine in lipiodol as a potential liver imaging agent. <i>Journal of Radioanalytical and Nuclear Chemistry</i> , 2017, 311, 263-268.	1.5	5
116	A compact solvent extraction based ⁹⁹ Mo/ ⁹⁹ mTc generator for hospital radiopharmacy. <i>Applied Radiation and Isotopes</i> , 2019, 143, 41-46.	1.5	5
117	Towards personalizing treatment strategies in mCRPC: can dual-tracer PET-CT provide insights into tumor biology, guide the optimal treatment sequence, and individualize decision-making (between Tj ETQq1 1 0.784314 rgBT /Overl disease course?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 1793-1797.	6.4	5
118	Technetium labeled doxorubicin loaded silk fibroin nanoparticles: Optimization, characterization and in vitro evaluation. <i>Journal of Drug Delivery Science and Technology</i> , 2020, 56, 101539.	3.0	5
119	Initial clinical evaluation of indigenous ⁹⁰ Y-DOTATATE in sequential duo-PRRT approach (¹⁷⁷ Lu-DOTATATE and ⁹⁰ Y-DOTATATE) in neuroendocrine tumors with large bulky disease: Observation on tolerability, ⁹⁰ Y-DOTATATE post- PRRT imaging characteristics (bremsstrahlung and PETCT) and early adverse effects. <i>World Journal of Nuclear Medicine</i> , 2021, 20, 73-81.	0.5	5
120	Production, characterization and in-vitro applications of single-domain antibody against thyroglobulin selected from novel T7 phage display library. <i>Journal of Immunological Methods</i> , 2021, 492, 112990.	1.4	5
121	Preparation and preliminary biological evaluation of a ¹⁶⁶ Ho labeled polyazamacrocycle for possible use as an intravascular brachytherapy (IVBT) agent. <i>Applied Radiation and Isotopes</i> , 2006, 64, 462-469.	1.5	4
122	Preparation and biological studies of ¹²⁵ I-DOTA-TATE. <i>Applied Radiation and Isotopes</i> , 2007, 65, 687-690.	1.5	4
123	Synthesis and bioevaluation of a ¹⁷⁷ Lu-labeled unsymmetrical cationic porphyrin derivative as a tumor targeting agent. <i>Journal of Radioanalytical and Nuclear Chemistry</i> , 2016, 307, 1537-1544.	1.5	4
124	Radiochemical studies, pre-clinical investigation and preliminary clinical evaluation of ¹⁷⁰ Tm-EDTMP prepared using in-house freeze-dried EDTMP kit. <i>Applied Radiation and Isotopes</i> , 2017, 122, 7-13.	1.5	4
125	Preparation and comparative evaluation of ^{99m} Tc- ^{99m} Tc-HYNIC-PEG ₂ -NGR and ^{99m} Tc-HYNIC-PEG ₂ -NGR as tumor targeting molecular imaging probes. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2018, 61, 68-76.	1.0	4
126	The rationality of combining second-generation antiandrogens with ¹⁷⁷ Lu-PSMA or its alpha-emitting congeners for better and durable results. <i>Nuclear Medicine Communications</i> , 2018, 39, 1061-1063.	1.1	4

#	ARTICLE	IF	CITATIONS
127	Formulation and radiochemical evaluation of a freeze-dried mixed peptide kit for the preparation of ⁶⁸ Ga-labeled peptides for PET imaging of somatostatin receptor positive neuroendocrine cancers. <i>Journal of Radioanalytical and Nuclear Chemistry</i> , 2014, 302, 1259-1264.	1.5	3
128	Sequential Duoâ€“Peptide Receptor Radionuclide Therapy With Indigenous ⁹⁰ Y-DOTATATE and ¹⁷⁷ Lu-DOTATATE in Large-Volume Neuroendocrine Tumors. <i>Clinical Nuclear Medicine</i> , 2020, 45, 714-715.	1.3	3
129	Quercetin induces proteolysis of mesenchymal marker vimentin through activation of caspase-3, and decreases cancer stem cell population in human papillary thyroid cancer cell line.. <i>Phytomedicine Plus</i> , 2021, 1, 100108.	2.0	3
130	One decade of 'Bench-to-Bedside' peptide receptor radionuclide therapy with indigenous [¹⁷⁷ Lu]Lu-DOTATATE obtained through 'Direct' neutron activation route: lessons learnt including practice evolution in an Indian setting. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 10, 178-211.	1.0	3
131	Synthesis of ^{99m} Tc-Nitrido Heterocomplex of Piperidine and <i>In Vitro</i> and <i>In Vivo</i> Evaluation of Its Affinity for Sigma Receptors. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2008, 23, 34-42.	1.0	2
132	Formulation of Patient Dose of ¹⁷⁷ Lu-DOTA-TATE in Hospital Radiopharmacy in India: Preparation Using In Situ Methodology Vis-a-Vis Freeze-Dried Kit. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2014, 29, 301-302.	1.0	2
133	Radiosynthesis and evaluation of a ^{99m} Tc-folic acid radiotracer prepared using [^{99m} TcN(PNP)] ²⁺ metal fragment. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 1329-1332.	2.2	2
134	Developing a dedicated comprehensive \pm -radionuclide therapy program. <i>Nuclear Medicine Communications</i> , 2017, 38, 103-105.	1.1	2
135	¹⁷⁰ Tm-EDTMP. <i>Clinical Nuclear Medicine</i> , 2017, 42, 235-236.	1.3	2
136	Novel radioassay for anti-thyroperoxidase autoantibodies using protein A coupled magnetizable cellulose particles as an immunoadsorbent. <i>Journal of Radioanalytical and Nuclear Chemistry</i> , 2020, 323, 1041-1046.	1.5	2
137	On the Separation of Yttrium-90 from High-Level Liquid Waste: Purification to Clinical-Grade Radiochemical Precursor, Clinical Translation in Formulation of ⁹⁰ Y-DOTATATE Patient Dose. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2021, 36, 143-159.	1.0	2
138	Therapeutic Multidose Preparation of a Ready-to-Use ¹⁷⁷ Lu-PSMA-617 Using Carrier Added Lutetium-177 in a Hospital Radiopharmacy and Its Clinical Efficacy. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2021, 36, 682-692.	1.0	2
139	Bulk Scale Formulation of Therapeutic Doses of Clinical Grade Ready-to-Use Lu-DOTA-TATE: The Intricate Radiochemistry Aspects. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2017, 32, 266-273.	1.0	2
140	Clinical Efficacy of Sodium [^{99m} Tc] Pertechnetate from Low Specific Activity ⁹⁹ Mo/ ^{99m} Tc Autosolex Generator in Hospital Radiopharmacy Centre. <i>Nuclear Medicine Review</i> , 2020, 23, 1-14.	0.5	2
141	Clinical Dose Preparation of [¹⁷⁷ Lu]Lu-DOTA-Pertuzumab Using Medium Specific Activity [¹⁷⁷ Lu]LuCl ₃ for Radioimmunotherapy of Breast and Epithelial Ovarian Cancers, with HER2 Receptor Overexpression. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2022, 37, 384-402.	1.0	2
142	Single vial freeze-dried TRODAT-1 kit: Preparation and demonstration of clinical efficacy of [^{99m} Tc]TRODAT-1 in Indian scenario. <i>Applied Radiation and Isotopes</i> , 2015, 96, 57-62.	1.5	1
143	Microarray immunoassay for thyrotropin on track-etched membranes using radiotracers. <i>Journal of Radioanalytical and Nuclear Chemistry</i> , 2019, 322, 99-104.	1.5	1
144	Purification of ⁹⁹ Mo and ^{99m} Tc from radioactive traces of Nb, Zr, and Y impurities: method applicable in the purification of the spent ¹⁰⁰ / ⁹⁹ Moâ€“ ^{99m} Tc generator. <i>Journal of Radioanalytical and Nuclear Chemistry</i> , 2019, 322, 809-815.	1.5	1

#	ARTICLE	IF	CITATIONS
145	Clinical utility of indigenously formulated single-vial lyophilized HYNIC-TOC kit in evaluating Gastro-entero Pancreatic neuro endocrine tumours. <i>Asia Oceania Journal of Nuclear Medicine and Biology</i> , 2014, 2, 30-41.	0.1	1
146	Estimation of Absorbed Doses of Indigenously Produced ¹⁷⁷ Lu-DOTA-TATE PRRT in Normal Organs and Tumor Lesions in Patients of Metastatic Neuroendocrine Tumors: Comparison with No-Carrier-Added ¹⁷⁷ Lu-DOTA-TATE and the Trend with Multiple Cycles. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2022, 37, 214-225.	1.0	1
147	Automated Radiochemical Synthesis of Pharmaceutical Grade [¹⁸ F]FLT using 5 ³ N ³ Boc ⁵ TM ³ OC ³ dimethoxytrityl ³ TM ³ OC ³ nosyl ³ thymidine precursor and its Sep ³ Pak ³ Purification employing Selective Elution from Reversed Phase. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2022,...	1.0	1
148	Preparation and Evaluation of ^{99m} Tc(CO) ₃ -Labeled Pentadecanoic Acid Derivative and Its Suspension in Lipiodol. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2009, 24, 503-507.	1.0	0
149	Formulation of clinical-scale ¹⁷⁷ Lu-PSMA-617: From laboratory to clinics. <i>Nuclear Medicine and Biology</i> , 2016, 43, 836.	0.6	0
150	Synthesis of O-(¹⁸ F)fluoropropan-2 ² -yl)-l-tyrosine (1-[¹⁸ F]FPT) via Ni(II) complex of (S) tyrosine schiff TM s base precursor. <i>Journal of Radioanalytical and Nuclear Chemistry</i> , 2017, 314, 483-490.	1.5	0
151	Biodistribution and Dosimetry of Indigenously Produced ¹³¹ I-Rituximab in B-Cell Lymphoma: Pilot Study Estimating Patient-Specific Dose Comparing 2 Different Dosimetric Methods. <i>Journal of Nuclear Medicine Technology</i> , 2019, 47, 292-299.	0.8	0
152	Clinical efficacy of Sep-Pak ³ assisted one pot automated synthesis of pharmaceutical grade [¹⁸ F]FLT using 5 ³ -O-(benzoyl)-2,3 ³ -anhydrothymidine precursor. <i>Journal of Radioanalytical and Nuclear Chemistry</i> , 2021, 327, 585-596.	1.5	0
153	On the production of pharmaceutical grade indium-111-chloride in the medical cyclotron from natural cadmium target and its use in formulation of diagnostic patient dose of ¹¹¹ In-pentetreotide for imaging somatostatin receptor overexpression. <i>Journal of Radioanalytical and Nuclear Chemistry</i> , 2021, 328, 835-846.	1.5	0
154	Prospective evaluation of organ-specific dose and lesional doses following therapeutic [¹⁷⁷ Lu]Lu-EDTMP administration in patients with multiple skeletal metastases and its correlation with clinical hematological toxicity. <i>Nuclear Medicine Communications</i> , 2021, 42, 1076-1084.	1.1	0
155	Evaluation of Different Methods for the Detection of Anti- Thyroglobulin Autoantibody: Prevalence of Anti-Thyroglobulin Autoantibody and Anti-Microsomal Autoantibody in Thyroid Cancer Patients. <i>Indian Journal of Clinical Biochemistry</i> , 0, , 1.	1.9	0